Breaking News, Collaborations & Alliances

Tetra Pharm Technologies & Glysious Partner to Develop Transdermal Combination Drugs

Aim to revolutionize transdermal release of ‘difficult-to-formulate’ compounds targeting the endocannabinoid system.

Author Image

By: Charlie Sternberg

Associate Editor

Tetra Pharm Technologies and Glysious have entered a strategic collaboration aimed at developing a transdermal drug delivery system that will complement several of Tetra Pharm Technologies’ pipeline candidates. The joint invention aims to revolutionize transdermal release of “difficult-to-formulate” compounds targeting the endocannabinoid system.   Tetra Pharm Technologies has focused intensively on formulation expertise, while Glysious has worked rigorously on the developmen...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters